不同剂量瑞舒伐他汀对急性冠脉综合征患者血NF-κB，sICAM-1表达的影响

Effect of Different Doses of Rosuvastatin on Blood NF-κB and sICAM-1 in Patients with Acute Coronary Syndrome

关键词:  瑞舒伐他汀  急性冠脉综合征  NF-κB  sICAM-1

Key words:  rosuvastatin  acute coronary syndrom  NF-κB  sICAM-1

摘要:

目的 探讨不同剂量的瑞舒伐他汀对急性冠脉综合征(ACS)患者血核因子-κB(NF-κB)、可溶性细胞间黏附因子(sICAM-1)表达的影响。方法 ACS患者随机分为瑞舒伐他汀10 mg组和20 mg组，另设健康对照组。治疗前及治疗后检测血NF-κB，sICAM-1及血脂等指标，进行治疗前后比较及组间比较。结果 ACS患者血NF-κB，sICAM-1水平较健康对照组显著升高(P<0.01)，治疗4周后，瑞舒伐他汀10，20 mg组血NF-κB，sICAM-1活性下降，治疗前后有显著性差异。治疗后瑞舒伐他汀20 mg组比10 mg组血NF-κB，sICAM-1水平下降更显著(P<0.05)。结论 瑞舒伐他汀能有效降低ACS患者血NF-κB，sICAM-1水平，且大剂量作用更明显。

Abstract:

OBJECTIVE To investigate the effect of different doses of rosuvastatin with acute coronary syndrome (ACS) patients on blood nuclear factor of kappa-B(NF-κB) and soluble intercellular adhesion molecule-1(sICAM-1) expression. METHODS ACS patients were randomized into rosuvastatin 10 mg group and 20 mg group. And forty healthy people were set as control group. Levels of blood NF-κB and sICAM-1 and blood lipids were measured between before treatment and after treatment. RESULTS Levels of blood NF-κB and sICAM-1 in ACS patients were significantly higher than healthy control group(P<0.01). After 4 weeks’ treatment, levels of blood NF-κB and sICAM-1 were decreased in rosuvastatin 10 mg group and 20 mg group. After treatment, levels of blood NF-κB and sICAM-1 were decreased more significantly in rosuvastatin 20 mg group than 10 mg group(P<0.05). CONCLUSION Rosuvastatin can reduce the levels of blood NF-κB and sICAM-1 in ACS patients, and high dose group is more evident.